Otsuka Pharmaceutical and Lundbeck's Rexulti, or brexpiprazole, has gained FDA approval for the treatment of agitation related to Alzheimer's disease, making it the first treatment for the condition. The drug was previously approved for treatment of adults dealing with schizophrenia and major depressive disorder.